Targeting embryonic signaling pathways in cancer therapy

Expert Opinion on Therapeutic Targets

Volumn 16, Issue 1, 2012, Pages 131-145

  Harris, Pamela Jo ^a   Speranza, Giovanna ^a   Dansky Ullmann, Claudio ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Cancer stem cells; Developmental pathways; Embryonic signaling pathways; Hedgehog; Notch; Wnt

Indexed keywords

2,4 DIAMINO QUINAZOLINE; ANTINEOPLASTIC AGENT; BMS 833923; BMS 906024; ERISMODEGIB; GANT 58; GANT 61; ICG 001; IPI 926; LEQ 506; MK 0752; NOTCH RECEPTOR; NSC 668036; PF 04449913; PF 103084014; PNU 74654; RO 4929097; ROBOTNIKININ; SEMAGACESTAT; SONIC HEDGEHOG PROTEIN; TAK 441; UNCLASSIFIED DRUG; VISMODEGIB; WNT PROTEIN; XAV 939;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADVANCED CANCER; CANCER STEM CELL; CANCER THERAPY; HUMAN; LEUKEMIA; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

ANIMALS; ANTINEOPLASTIC AGENTS; HEDGEHOG PROTEINS; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 84855883749     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.645808     Document Type: Review

References (114)

1. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non- small-cell lung cancer with mutated EGFR. N Engl J Med 2010;16:2380-8
2. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non- small-cell lung cancer. N Engl J Med 2010;363:1693-703
3. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16
4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
5. O'Brien CA, Kreso A, Jamieson CHM. Cancer stem cells and self-renewal. Clin Cancer Res 2010;16:3113-20
6. Yang ZJ, Wechsler-Reya RJ. Hit 'em where they live: targeting the cancer stem cell niche. Cancer Cell 2007;11:3-5 (Pubitemid 46054521)
7. Donnenberg VS, Donnenberg AD. Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis. J Clin Pharmacol 2005;45:872-7 (Pubitemid 41060226)
8. Takebe N, Ivy SP. Controversies in cancer stem cells: targeting embryonic signaling pathways. Clin Cancer Res 2010;16:3106-12
9. Haraguchi N, Inoue H, Tanaka F, et al. Cancer stem cells in human gastrointestinal cancers. Hum Cell 2006;19:24-9
10. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504-14 (Pubitemid 351267301)
11. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-8 (Pubitemid 37187480)
12. Curtis SJ, Sinkevicius KW, Li D, et al. Primary tumor genotype is an important determinant in identification of lung cancer propagating cells. Cell Stem Cell 2010;7:127-33
13. Kelleher FC, Fennelly D, Rafferty M. Common critical pathways in embryogenesis and cancer. Acta Oncol 2006;45:375-88 (Pubitemid 43884605)
14. Vivekanand P, Rebay I. Intersection of signal transduction pathways and development. Annu Rev Genet 2006;40:139-57 (Pubitemid 44956782)
15. Jiang J, Hui CC. Hedgehog signaling in development and cancer. Dev Cell 2008;15:801-12
16. Bolos V, Grego-Bessa J, de la Pompa JL. Notch signaling in development and cancer. Endocr Rev 2007;28:339-63 (Pubitemid 46984831)
17. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997;11:3286-305 (Pubitemid 28023954)
18. Takebe N, Harris PJ, Warren RQ, Ivy SP. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 2011;8:97-106
19. Hugo H, Ackland ML, Blick T, et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol 2007;213:374-83 (Pubitemid 47509716)
20. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006;66:9339-44 (Pubitemid 44623625)
21. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010;120:41-50
22. Ingham PW, McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes Dev 2001;15:3059-87 (Pubitemid 33115673)
23. Cohen MM Jr. Hedgehog signaling: endocrine gland development and function. Am J Med Genet A 2010;152A:238-44
24. Cohen MM Jr. Hedgehog signaling update. Am J Med Genet A 2010;152A:1875-914
25. Onishi H, Katano M. Hedgehog signaling pathway as a therapeutic target in various types of cancer. Cancer Sci 2011;102:1756-60
26. Kasper M, Regl G, Frischauf AM, Aberger F. GLI transcription factors: mediators of oncogenic Hedgehog signaling. Eur J Cancer 2006;42:437-45 (Pubitemid 43227920)
27. Gailani MR, Bale AE. Developmental genes and cancer: role of patched in basal cell carcinoma of the skin. J Natl Cancer Inst 1997;89:1103-9 (Pubitemid 27337923)
28. Xie J, Murone M, Luoh SM, et al. Activating smoothened mutations in sporadic basal cell carcinoma. Nature 1998;391:90-2 (Pubitemid 28079221)
29. Zurawel RH, Allen C, Chiappa S, et al. Analysis of PTCH/SMO/SHH pathway genes in medulloblastomas. Genes Chromosomes Cancer 2000;27:44-51
30. Ferretti E, De Smaele E, Miele E, et al. Concerted microRNA control of Hedgehog signaling in cerebellar neuronal progenitor and tumor cells. Embo J 2008;27:2616-27
31. Kinzler KW, Bigner SH, Binger DD, et al. Identification of an amplified, highly expressed gene in a human glioma. Science 1987;236:70-3 (Pubitemid 17056814)
32. Roberts WM, Douglass EC, Peiper SC, et al. Amplification of the gli gene in childhood sarcomas. Cancer Res 1989;49:5407-13 (Pubitemid 19240482)
33. Tian H, Callahan CA, DuPree KJ, et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci USA 2009;106:4254-9
34. Yamasaki A, Kameda C, Xu R, et al. Nuclear factor kappa B-activated monocytes contribute to pancreatic cancer progression through the production of Shh. Cancer Immunol Immunother 2010;59:675-86
35. Ehtesham M, Sarangi A, Valadez JG, et al. Ligand-dependent activation of the hedgehog pathway in glioma progenitor cells. Oncogene 2007;26:5752-61 (Pubitemid 47312811)
36. Watkins DN, Berman DM, Burkholder SG, et al. Hedgehog signaling within airway epithelial progenitors and in small cell lung cancer. Nature 2003;422:313-17 (Pubitemid 36378358)
37. Berman DM, Karhadkar SS, Maitra A, et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumors. Nature 2003;425:846-51 (Pubitemid 37351469)
38. Kubo M, Nakamura M, Tasaki A, et al. Hedgehog signaling pathway is a new therapeutic target for patients with breast cancer. Cancer Res 2004;64:6071-4 (Pubitemid 39129406)
39. Rubin LL, de Sauvage FJ. Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 2006;5:1026-33 (Pubitemid 44835129)
40. Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 2002;16:2743-8 (Pubitemid 35253140)
41. Tremblay MR, Lescarbeau A, Grogan MJ. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 2009;52:4400-18
42. Travaglione V, Peacock CD, MacDougall J, et al. A novel HH pathway inhibitor, IPI-926, delays recurrence post-chemotherapy in a primary human SCLC xenograft model. Proc Am Assoc Cancer Res 2008;49:4611
43. Von Hoff DD, LoRusso MP, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal cell carcinoma. N Engl J Med 2009;361:1164-72
44. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0499. N Engl J Med 2009;361:1173-8
45. Lauth M, Bergstrom A, Shimokawa T, Toftgard R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc Natl Acad Sci USA 2007;104:8455-60 (Pubitemid 47175509)
46. Bolos V, Grego-Bessa J, Luis de la Pompa J. Notch signaling in development and cancer. Endocr Rev 2007;28:339-63 (Pubitemid 46984831)
47. Dontu G, Jackson KW, McNicholas E, et al. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004;6:R606-15
48. Kopan R, Ilagan MX. The canonical notch signaling pathway: unfolding the activation mechanism. Cell 2009;137:216-33
49. Fortini ME. Notch signaling: the core pathway and its posttranslational regulation. Dev Cell 2009;16:633-47
50. Pannuti A, Foreman K, Rizzo P, et al. Targeting notch to target cancer stem cells. Clin Cancer Res 2010;16:3141-52
51. Mailhos C, Modlich U, Lewis J, et al. Delta4, an endothelial specific notch ligand expressed at sites of physiological and tumor angiogenesis. Differentiation 2001;69:135-44 (Pubitemid 33755062)
52. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of Notch1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269-71 (Pubitemid 39336870)
53. Fan X, Mikolaenko I, Elhassan I, et al. Notch1 and Notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004;64:7787-93 (Pubitemid 39446911)
54. Balint K, Xiao M, Pinnix CC, et al. Activation of Notch1 signaling is required for beta-catenin mediated human primary melanoma progression. J Clin Invest 2005;115:3166-76 (Pubitemid 41567581)
55. Collins BJ, Kleeberger W, Ball DW. Notch in lung development and lung cancer. Semin Cancer Biol 2004;14:357-64 (Pubitemid 38993637)
56. Miyamoto Y, Maitra A, Ghosh B, et al. Notch mediates TGFalpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003;3:565-76 (Pubitemid 36808651)
57. Jundt F, Anagnostopoulos I, Forster R, et al. Activated Notch1 signaling promotes tumor cell proliferation and survival in hodgkin and anaplastic large cell lymphoma. Blood 2002;99:3398-403 (Pubitemid 34525322)
58. Reedijk M, Odorcic S, Chang L, et al. High level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530-7 (Pubitemid 41330622)
59. Pece S, Serresi M, Santolini E, et al. Loss of negative regulation by numb over notch is relevant to human breast carcinogenesis. J Cell Biol 2004;167:215-21 (Pubitemid 39435065)
60. Strizzi L, Postovit LM, Margaryan NV, et al. Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol 2009;4:67-78
61. Topczewska JM, Postovit LM, Margaryan NV, et al. Embryonic and tumorigenic pathways converge via nodal signaling: role in melanoma and aggressiveness. Nat Med 2006;12:925-32 (Pubitemid 44175144)
62. Costa FF, Seftor EA, Bischof JM, et al. Epigenetically reprogramming metastatic tumor cells with an embryonic microenvironment. Epigenomics 2009;1:387-98
63. Pinnix CC, Herlyn M. The many faces of Notch signaling in skin-derived cells. Pigment Cell Res 2007;20:458-65 (Pubitemid 47568831)
64. Hardy KM, Kirschmann DA, Seftor EA, et al. Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res 2010;70:10340-50
65. Strizzi L, Hardy KM, Kirsammer GT, et al. Embryonic signaling in melanoma: potential for diagnosis and therapy. Lab Invest 2011;91:819-24
66. ClinicalTrials.gov Bethesda, MD: National Institutes of Health, 2011. Available from: www.clinicaltrials.gov [Last accessed 9 December 2011]
67. Curry CL, Reed LL, Golde TE, et al. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene 2005;24:6333-44 (Pubitemid 41486467)
68. Wang M, Wu L, Wang L, Xin X. Downregulation of Notch1 by gamma-secretase inhibition contributes to cell growth inhibition and apoptosis in ovarian cancer cells A2780. Biochem Biophys Res Commun 2010;393:144-9
69. Paris D, Quadros A, Patel N, et al. Inhibition of angiogenesis and tumor growth by beta and gamma secretase inhibitors. Eur J Pharmacol 2005;514:1-15 (Pubitemid 40692758)
70. Luistro L, He W, Smith M, et al. Preclinical profile of a potent gamma-secretase inhibitor targeting Notch signaling with in vivo efficacy and 69. pharmacodynamic properties. Cancer Res 2009;69:7672-80
71. Konishi J, Kawaguchi KS, Vo H, et al. gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 2007;67:8051-7 (Pubitemid 47395139)
72. Watters JW, Cheng C, Majumder PK, et al. De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model. Cancer Res 2009;69:8949-57
73. Wei P, Walls M, Qiu M, et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 2010;9:1618-28
74. Yan M. Therapeutic promise and challenges of targeting DLL4/NOTCH1. Vasc Cell 2011;3:17-21
75. Real PJ, Tosello V, Palomero T, et al. gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 2009;15:50-8
76. Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signaling inhibits tumor growth by deregulating angiogenesis. Nature 2006;444:1083-7 (Pubitemid 46018529)
77. Dufraine J, Funahashi Y, Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008;27:5132-7
78. Yan M, Callahan CA, Beyer JC, et al. Chronic DLL4 blockade induces vascular neoplasms. Nature 2010;463:E6-7
79. Li JL, Harris AL. Crosstalk of VEGF and notch pathways in tumor angiogenesis: therapeutic implications. Front Biosci 2009;14:3094-110
80. Hoey T, Yen WC, Axelrod F, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168-77
81. Smith D, Eisenberg P, Stagg R, et al. A first in human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells in patients with advanced solid tumors.. 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; 16 - 19 November 2010; Berlin, Germany. Available from: http://www.oncomed.com/news/pr/Study1posterfinalNov10.pdf
82. Li K, Li Y, Wu W, et al. Modulation of notch signaling by antibodies specific for the extracellular negative regulatory region of Notch3. J Biol Chem 2008;283:8046-54
83. Funahashi Y, Hernandez SL, Das I, et al. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Cancer Res 2008;68:4727-35
84. Moellering RE, Cornejo M, Davis TN, et al. Direct inhibition of the NOTCH transcription factor complex. Nature 2009;462:182-8
85. Grigoryan T, Wend P, Klauss A, Birchmeier W. Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. Genes Dev 2008;22:2308-41
86. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006;127:469-80
87. Takahashi N, Maeda K, Ishihara A, et al. Regulatory mechanism of osteoclastogenesis by RANKL and Wnt signals. Front Biosci 2011;16:21-30
88. Lustig B, Behrens J. The Wnt signaling pathway and its role in tumor development. J Cancer Res Clin Oncol 2003;129:199-221 (Pubitemid 36713796)
89. Dominguez I, Sonenshein GE, Seldin DC. CK2 and its role in Wnt and NF-kappaB signaling: Linking development and cancer. Cell Mol Life Sci 2009;66:1850-7
90. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006;281:22429-33
91. Reya T, Clevers H. Wnt signaling in stem cells and cancer. Nature 2005;434:843-50 (Pubitemid 40558990)
92. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67
93. Morin PJ, Sparks AB, Korinek V, et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997;275:1787-90 (Pubitemid 27136715)
94. Clevers H. Axin and hepatocellular carcinomas. Nat Genet 2000;24:206-8 (Pubitemid 30132183)
95. Dahmen RP, Koch A, Denkhaus D, et al. Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res 2001;61:7039-43 (Pubitemid 32946492)
96. Simon M, Grandage VL, Linch DC, Khwaja A. Constitutive activation of the Wnt/beta-catenin signaling pathway in acute myeloid leukemia. Oncogene 2005;24:2410-20 (Pubitemid 40546699)
97. Jue SF, Bradley RS, Rudnicki JA, et al. The mouse Wnt-1 gene can act via a paracrine mechanism in transformation of mammary epithelial cells. Mol Cell Biol 1992;12:321-8
98. Sardawi SJ, O'Toole SA, Sutherland RL, Musgrove EA. Dysregulation of Hedgehog, Wnt and Notch signaling pathways in breast cancer. Histol Histopathol 2009;24:385-98
99. Hiltunen MO, Alhonen L, Koistinaho J, et al. Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma. Int J Cancer 1997;70:644-8 (Pubitemid 27158441)
100. Costa VL, Henrique R, Ribeiro FR, et al. Epigenetic regulation of Wnt signaling pathway in urological cancer. Epigenetics 2010;5:343-51
101. Yao H, Ashihara E, Maekawa T. Targeting the Wnt/beta-catenin signaling pathway in human cancers. Expert Opin Ther Targets 2011;15:873-87
102. Takahashi-Yanaga F, Kahn M. Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 2010;16:3153-62
103. Dihlmann S, Siermann A, von Knebel Doeberitz M. The nonsteroideal anti-inflammatory drugs aspirin and indomethacin attenuate beta-catenin/TCF-4 signaling. Oncogene 2001;20:645-53 (Pubitemid 32156189)
104. Grosch S, Tegeder I, Niederberger E, et al. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001;15:2742-4
105. Chen B, Dodge ME, Tang W, et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nat Chem Biol 2009;5:100-7
106. Hunag SM, Mishina YM, Liu S, et al. Tankyrase inhibition stabilizes axin and 105. antagonizes Wnt signaling. Nature 2009;461:614-20
107. Wei W, Chua MS, Grepper S, So S. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cell in vitro and in vivo. Int J Cancer 2010;126:2426-36
108. Lepourcelet M, Chen YN, France DS, et al. Small molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell 2004;5:91-102 (Pubitemid 38121599)
109. Emami KH, Nguyen C, Ma H, et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transcription. Proc Natl Acad Sci USA 2004;101:12682-7 (Pubitemid 39122083)
110. Grandy D, Shan J, Zhang X, et al. Discovery and characterization of a small molecule inhibitor of the PDZ domain of dishevelled. J Biol Chem 2009;284:16256-63
111. You L, He B, Xu Z, et al. An anti-Wnt2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res 2004;64:5385-9 (Pubitemid 39006560)
112. Kiesslich T, Alinger B, Wolkersdorfer GW, et al. Active Wnt signalling is associated with low differentiation and high proliferation in human biliary tract cancer in vitro and in vivo and is sensitive to pharmacological inhibition. Int J Oncol 2010;36:49-58
113. Yde CW, Frogne T, Lykkesfeldt AF. Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT. Cancer Lett 2007;256:229-37 (Pubitemid 47418349)
114. Duncan JS, Gyenis L, Lenehan J, et al. An unbiased evaluation of CK2 inhibitors by chemoproteomics. Mol Cell Proteomics 2008;7:1077-88